Mobile Menu
Deals & Transactions

Conyers advises Axovant Sciences Ltd. on its $315 million IPO

Conyers Dill & Pearman advised Axovant Sciences Ltd. on its highly successful underwritten initial public offering of 21,000,000 of its shares, including exercise in full of the greenshoe option, for a total fundraising of $315 million. Roivant Sciences Ltd., the parent company, retains 75% of the shares. This is thought to be the biggest New York IPO in the biotechnology sector for at least 20 years and it is the first New York biotech IPO to use a Bermuda company as the listing vehicle.

Robert Alexander, Carol Clarke and Neil Henderson from Conyers Bermuda worked on the matter.

 


Neil Henderson
Director

BERMUDA   +1 441 298 7846



Accolades
_

"Few firms can come close to Conyers on one critical metric, and this is the breadth of the client base."
- IFLR1000

expertise

Corporate


Related Jurisdictions

Bermuda


Related International Markets

Bermuda


Media Contact

For media enquiries, please contact media@conyersdill.com

Deals & Transactions

Conyers advises Axovant Sciences Ltd. on its $315 million IPO

Conyers Dill & Pearman advised Axovant Sciences Ltd. on its highly successful underwritten initial public offering of 21,000,000 of its shares, including exercise in full of the greenshoe option, for a total fundraising of $315 million. Roivant Sciences Ltd., the parent company, retains 75% of the shares. This is thought to be the biggest New York IPO in the biotechnology sector for at least 20 years and it is the first New York biotech IPO to use a Bermuda company as the listing vehicle.

Robert Alexander, Carol Clarke and Neil Henderson from Conyers Bermuda worked on the matter.

 


Neil Henderson
Director

BERMUDA   +1 441 298 7846



 

expertise

Corporate


JURISDICTION(S)

Bermuda


International Office(s)

Bermuda